Compare Gilead Sciences, Inc. (GILD) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Banco Santander SA — how do they compare? Gilead Sciences, Inc. trades at $150.89 (market cap $182.40B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Gilead Sciences, Inc. and Banco Santander SA are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Banco Santander SA for 55 Days on average.
| GILD | SAN | |
|---|---|---|
Market Cap | $182.40B | $192.86B |
Volume | 4,469,821 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $155.80 | $15.05 |
52-Week Low | $116.74 | $9.65 |
Typical Hold Time | 111 Days | 55 Days |
Enterprise Value | $205.46B | $360.86B |
Dividend Yield | 2.23% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
